Full-Time
Director Medical Affairs
Liver Strategy
Gilead Sciences
10,001+ employees
Biopharmaceutical firm developing HIV/AIDS therapies
Compensation Overview
$243.1k - $314.6k/yr
Company Historically Provides H1B Sponsorship
San Mateo, CA, USA
Hybrid
On-site presence in Foster City, CA with hybrid eligibility.
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Gilead Sciences
See people who can refer or advise you
- Advanced healthcare or scientific degree required (MD, PharmD, PhD, or equivalent) with at least 8+ years of experience
- Experience in Medical Affairs within the biopharmaceutical industry, including leadership roles in strategy and content governance.
- Demonstrated expertise in medical material development and review processes (MRC/MLR/PRC), including understanding of promotional vs. non-promotional standards.
- Proven ability to translate complex medical strategy into clear tactical execution and external scientific communication.
- Excellent written and verbal communication skills, with experience developing scientific narratives and presentations.
- Strong project and program management capabilities, including ability to manage multiple workstreams, agencies, and timelines.
- Demonstrated success operating in a highly matrixed, cross-functional environment and leading through influence.
- Ability to travel domestically up to ~30%, including occasional weekends, as required.
- Lead development of overarching USMA Liver strategy for HCP engagement, scientific exchange, and medical education across PBC and HDV, aligned with enterprise priorities and evidence plans.
- Translate USMA Liver strategy into executable medical tactics, including field-facing materials, scientific narratives, congress strategies, symposia content, advisory boards, and digital engagement approaches.
- Serve as a senior Medical Affairs thought partner to Field Medical leadership, ensuring resources are field-ready, impactful, and aligned to priority HCP and KOL audiences.
- Own end-to-end medical resource and content operations for USMA Liver: oversee internal and external (agency) development, timelines, version control, and quality standards.
- Lead U.S. Medical Review Committee (MRC) governance for Liver materials, including preparation, submission, facilitation of review discussions, incorporation of feedback, and driving materials to approval.
- Ensure pull-through and appropriate adaptation of Global medical content for U.S. use, and oversee development of original U.S.-specific liver medical materials.
- Operationalize approved resources by coordinating training, launch, distribution, and adoption across field medical, digital platforms (e.g., CLM/MedDocs), and cross-functional teams.
- Maintain lifecycle management of liver medical assets, including renewals, expirations, proactive updates, and inventory of live materials.
- Lead HDV tactical planning and execution, including Annual Encore planning, congress deliverables, and ad hoc initiatives based on evolving priorities.
- Shape external scientific narrative by translating emerging clinical, real-world, and guideline data into clear, balanced, and compliant scientific communications.
- Partner cross-functionally with Legal, Regulatory, Commercial, HEOR, GMA, Clinical, Training, and Operations to ensure aligned, integrated, and compliant execution.
- Drive operational excellence, clear prioritization, and efficient use of resources across projects, vendors, and assigned budget areas.
- Contribute to digital and innovation strategy for USMA Liver, including evaluation and deployment of digital and AI-enabled solutions to enhance insight generation and medical education.
- Uphold Gilead core values and ensure all activities comply with applicable laws, regulations, and internal policies.
- Experience with digital medical content and innovation approaches to HCP education preferred.
- Strong background in liver disease (PBC, viral hepatitis, or related areas) strongly preferred.
- 8-12+ years of relevant experience listed above
Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Foster City, California
Founded
1987
Get referred to Gilead Sciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA approval in June 2026 for Trodelvy as first-line mTNBC treatment expands market to 75,000+ patients globally.
- Trodelvy+Keytruda reduces progression or death risk by 35%, establishing new standard of care in first-line TNBC.
- Gilead acquired Arcellx, Ouro Medicines, and Tubulis in 2026 to diversify oncology pipeline beyond HIV.
What critics are saying
- AstraZeneca's Enhertu threatens Trodelvy's $2.8B oncology revenue target by 2028 with 50-54% progression risk reduction.
- High debt with 0.89 debt-to-equity ratio constrains funding for additional oncology acquisitions after $21B Immunomedics deal.
- Trodelvy's safety profile including leukopenia and anemia may trigger stricter reimbursement restrictions in 2026-2027.
What makes Gilead Sciences unique
- Trodelvy is the first antibody-drug conjugate approved for first-line metastatic triple-negative breast cancer globally.
- Gilead uniquely anchors its portfolio with HIV franchise generating 67% of revenue while building oncology as second engine.
- Gilead holds patent protection for top HIV drugs until 2036, avoiding near-term patent cliffs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid family time off and paid parental time off
Generous 401(k) contribution matching
Comprehensive medical plans that cover both physical and mental healthcare
Global Wellbeing Reimbursement
Time Off
Global Volunteer Day
Giving Together Program
Employee Support Programs
Flexible Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%SFU chemists supercharge antiviral drug discovery. July 22, 2026 by Robyn Stubbs As the world faces new and often untreatable viral threats, Simon Fraser University researchers have found a way to cut years off the time it takes to discover antiviral drugs. The research enables scientists to quickly create large libraries of nucleoside analogs (NAs), compounds that mimic the building blocks of DNA and RNA and are widely used to treat cancer and viral infections such as HIV and hepatitis. The new method could significantly reduce the time and resources needed for early-stage drug discovery. "This is a game changer for making and modifying nucleosides," explains Robert Britton, chemistry professor and lead author of the study. "In an emerging outbreak, the more compounds you can screen, the better your chances of finding something effective. With this method, we can produce libraries 10 to 100 times larger in just weeks, rather than months or years." "We have lots of pain killers and a wide collection of antibiotics, but we don't have a good of a panel of antivirals, which is why viral outbreaks like COVID-19, or Ebola, or hantavirus scare people so much," says Britton. "Finding viable drug candidates is extremely challenging." To identify new treatments, scientists typically screen libraries of molecules to find promising "hits" for further development. This approach helped companies like Merck & Co. and Gilead Sciences develop early COVID-19 treatments. But in antiviral discovery, scale matters. Generating large libraries of molecules to screen has been limited by complex chemistry. In the study, published in Science, Britton and his research team which included scientists at the drug company Merck, began with a single, scalable building block - one versatile molecular starting point that can be produced in large quantities. Using a light-driven reaction, the team attached different nucleobases to this core structure, quickly generating a library of more than 70 NAs. To test whether the approach could find useful drug candidates, the researchers screened the library against HIV at the Pantophlet Laboratory at SFU, led by health sciences professor Ralph Pantophlet. Three compounds showed activity comparable to approved HIV therapies. "Most of the compounds in our library were entirely new," Britton says. "A few had been made before, but it took other groups longer to synthesize those molecules, and they were not able to modify and improve them as readily." Building on earlier SFU research. This study builds on earlier work from the Britton Lab at SFU. Traditionally, synthesizing nucleoside analogs requires a complex, 20-step process that can take months or years. In 2020, Britton and collaborators reduced that process to just a few steps completed in about a week.
Staggering results show hiv-transmission reduced 100% with twice-yearly Lenacapavir injection. Jun 9, 2026 A 2-stage trial testing a new and acclaimed HIV-prevention drug has shown almost unthinkable results of no new infections among a sample size of 3,200 participants. Called PURPOSE 1, the aim of the first trial was testing a subcutaneous injection of the drug Lenacapavir given twice a year to people in a high-HIV-incidence country, which in this case was Uganda or South Africa. The results were nothing short of extraordinary - 100% efficacy, not a single young woman contracted HIV. This was followed up by PURPOSE 2, which expanded the geographical area significantly to more countries on more continents, and expanded the pool of individuals from beyond just young women to men - and to those of all ages. 5,000 participants took part. The result was the same: 99.9% reduction in infection rates. Both were considered phase 3 clinical trials, and were conducted in a randomized, double-blinded protocol, but were not tested against a placebo. Instead, the Lenacapavir injections were compared to the current standard of HIV prevention - a pill called Truvada or Descovy taken daily. These both were also found to prevent HIV transmission by 99.9% during development, but must be taken every day to achieve this level of protection. As anyone who's tried to stick to a once-a-day pill regime long-term will agree, it's not an easy thing to maintain month after month. By contrast, the twice-yearly injections are much easier to adhere to, and they also come with the added benefit of removing the social stigma of being seen taking a daily pill and therefore at risk of HIV transmission. This can be particularly alleviating in high-HIV-prevalent countries where male homosexuality is illegal, such as Uganda. Indeed the superiority of a twice-yearly injection was so clear that both PURPOSE trials were halted early over ethical reasons. A 52-week follow-up screened for HIV developments. Lenacapavir was named by Science Magazine as the Breakthrough of the Year in 2024, and was approved by the FDA for use in humans under the brand name Yeztugo. It works to break down the HIVs capsid shell by binding to an "highly conserved" protein on the exterior. That means that no matter how many times or into what form the virus mutates, the exterior shell protein remains - presenting the perfect target for the drug. In layman's terms, the drug then works through the protein to disrupt the capsid shell, which the virus 'takes down' and 'builds up' several times during its lifecycle with perfect geometric precision. The disruption prevents the virus from completing its life cycle. Initial R&D, regulation compliance, and proof of efficacy and safety requirements mean that producing Lenacapavir has cost its developer, Gilead Sciences, an undisclosed total cost that would be reasonable to estimate at well over a billion dollars based on normal pharma development costs. Gilead has nevertheless committed to providing the drug at cost in certain low-income regions and has licensed generic manufacturers to produce it for approximately $40 per year in 120 low and middle-income countries starting in 2027.
Tempus AI expands oncology data collaboration with Gilead Sciences through AI-driven platform access. April 10, 2026 Tempus AI, Inc. (Nasdaq: TEM), a Chicago-based technology company, announced an expanded multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at advancing Gilead's oncology pipeline through enterprise-wide access to Tempus's AI-driven Lens platform and multimodal real-world evidence datasets. The agreement covers multiple oncology indications; no specific drug candidates or therapeutic targets were disclosed as part of the transaction. Financial terms were not disclosed. Under the expanded arrangement, Gilead gains enterprise-wide access to the Tempus Lens platform, which integrates de-identified genomic, clinical, imaging, and outcomes data into a unified repository supported by AI-driven analytical tooling. Disclosed applications include trial design, indication selection, biomarker strategy, health outcomes analysis, and clinical real-world evidence generation. Tempus will also provide dedicated analytical services under the agreement. The collaboration represents an expansion of a pre-existing relationship in which Gilead had previously used Tempus data to inform oncology R&D initiatives, and follows on from a collaboration between Tempus and Daiichi Sankyo announced in March 2026. The collaboration is designed to operate across Gilead's oncology pipeline rather than in support of a single program. Gilead's oncology portfolio includes sacituzumab govitecan, axicabtagene ciloleucel, brexucabtagene autoleucel, and magrolimab, among other assets, though none were named as specific beneficiaries of the arrangement. The platform's stated functions - indication prioritization, patient stratification, biomarker pre-validation, and real-world evidence generation - are applicable across tumor types and development stages. Your email address will not be published. Required fields are marked *
Kymera Therapeutics will receive a $45 million milestone payment following Gilead Sciences' decision to exercise its option to exclusively licence KT-200, a first-in-class oral CDK2 molecular glue degrader development candidate. Gilead will advance the programme into IND-enabling studies, targeting an IND filing in 2027. KT-200 is expected to become the first molecular glue discovered by Kymera to enter clinical trials. The drug candidate demonstrated low-nanomolar degradation of CDK2 in preclinical testing, with robust activity in cancer cell lines and favourable safety profiles. It targets cancers driven by CCNE1 amplification, including advanced breast cancer. Under their collaboration agreement, Kymera is eligible for up to $750 million in total payments and has received $85 million to date. The company will also receive tiered royalties on net product sales.
Gilead to acquire Tubulis for up to $5B, expanding cancer ADC capabilities. April 7, 2026 Gilead Sciences has agreed to acquire German-based Tubulis for up to $5 billion, the companies said today, in a deal designed to expand the buyer's antibody-drug conjugate (ADC) capabilities with a focus on fighting cancer. Headquartered in Munich, privately held Tubulis has developed next-generation ADC candidates based on its own conjugation, linker and payload technologies intended to more selectively deliver diverse payloads to tumors deemed to be of high unmet need. The companies said Tubulis' programs and platforms have broad potential across multiple tumor types, complementing Gilead's development and commercialization expertise in oncology. "We like the strategic fit and deal terms of the Tubulis (private) acquisition," Daina M. Graybosch, PhD, senior managing director, immuno-oncology and a senior research analyst at Leerink Partners, wrote this morning in a research note. "This is more than an oncology bolt-on; we see real platform value in application of Tubulis' ADC technologies to other therapeutic areas, namely virology." Tubulis' lead pipeline candidate, TUB-040, is a sodium-dependent phosphate transport protein 2B (NaPi2b)-targeting topoisomerase-I inhibitor (TOPO1i) ADC that is now under study in the Phase Ib/II NAPISTAR1-01 trial (NCT06303505) assessing its safety, pharmacokinetics, and preliminary efficacy as a treatment for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). In October at the European Society for Medical Oncology (ESMO), Graybosch noted, Tubulis presented data for TUB-040 showing a confirmed 50% overall response rate (ORR) and a 60% unconfirmed ORR across dose levels and irrespective of target antigen - results that were competitive with more mature datasets from leading TOPO1i ADCs. "Though the dataset was early, and our primary outgoing question was how durability would mature, we suspect that Gilead saw durability maturing positively in their diligence," Graybosch added. "If TUB-040 proves active in NSCLC, the program could complement their Trodelvy and IO [immune-oncology] lung programs. We wonder if Gilead saw early clinical NSCLC data in their diligence and if excitement around the emerging signal drove some of Tubulis' valuation." Another Tubulis pipeline candidate, TUB-030, is a 5T4-targeting ADC that according to the companies has shown promising initial clinical data across various solid tumor types. TUB-030 is currently under study in the Phase I/IIa 5-STAR 1-01 trial (NCT06657222), a first-in-human study which aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TUB-030 as a monotherapy in patients with advanced solid tumors. Tubulis has said it is developing TUB-030 for up to 13 undisclosed solid tumor indications. Partners since 2024. The acquisition deal follows a two-year, up-to-$465 million collaboration with Tubulis launched in December 2024. Gilead gained access to Tubulis' Tubutecan and Alco5 platforms after signing an exclusive option and license agreement to discover and develop an ADC against a solid tumor target. At the time, Gilead agreed to pay Tubulis $20 million upfront, received an option that if exercised would have given Tubulis an additional $30 million - plus up to $415 million in payments tied to achieving development and commercialization milestones, as well as mid-single to low double-digit tiered royalties on sales of marketed products resulting from the collaboration. "Today's agreement follows a two-year collaboration with Tubulis, which has given us strong conviction in their programs and research capabilities," Gilead Chairman and CEO Daniel O'Day said in a statement. "The agreement to acquire Tubulis is a significant milestone in Gilead's progress in oncology. The company brings a clinical-stage candidate that is a potential new treatment for ovarian cancer, as well as a next-generation ADC platform and a promising early pipeline." "Bringing this potential into Gilead would further expand what is already the strongest and most diverse pipeline in our company's history," O'Day declared. Investors appeared less enthusiastic about the acquisition, as shares of Gilead dipped 1.7% in early Tuesday trading to $137.80 as of 12:01 p.m. ET. Tubulis is Gilead's third announced acquisition this year. The biotech giant announced plans in March to buy Ouro Medicines for up to $2.18 billion, and in February agreed to acquire Arcellx for up to $7.8 billion - for which it agreed last week to extend its tender offer until 5 p.m. ET on April 24. Under the acquisition deal, Gilead agreed to acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash payable at closing, and up to $1.85 billion in payments tied to milestones. The transaction is expected to close in the second quarter subject to expiration or termination of specified regulatory filings and other customary conditions. Upon closing of the deal, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation, building on its integrated discovery, manufacturing, and clinical capabilities to advance next generation ADCs. Gilead said it plans to finance the transaction with a combination of cash on hand and senior unsecured notes. Gilead finished 2025 with $10.605 billion of cash, cash equivalents and marketable debt securities, up from $9.991 billion as of December 31, 2024.